Ohcanbohtosat - Adrian Bot

Aiddostahte ozu
  1. 1
    Protective Role of Gamma Interferon during the Recall Response to Influenza Virus

    Protective Role of Gamma Interferon during the Recall Response to Influenza Virus Dahkki Adrian Bot, Simona Bot, Constantin A. Bona

    Almmustuhtton 1998
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL

    Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL Dahkki Zachary Roberts, Marc Better, Adrian Bot, Margo R. Roberts, Antoni Ribas

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

    Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Dahkki Adrian Bot, Thomas E. Tarara, Daniel J. Smıth, Simona Bot, Catherine M. Woods, Jeffry G. Weers

    Almmustuhtton 2000
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy

    Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy Dahkki Stephanie N. Shishido, Olivia Hart, Sujin Jeong, Aidan Moriarty, Darren Heeke, John M. Rossi, Adrian Bot, Peter Kühn

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice

    Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice Dahkki Adrian Bot, Daniel J. Smıth, Simona Bot, Anna C. Hughes, Tom Wolfe, Xin Lin, C. G. Woods, Matthias von Herrath

    Almmustuhtton 2001
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Autoreactive CD4+ T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway

    Autoreactive CD4+ T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway Dahkki Dirk Homann, Andreas Holz, Adrian Bot, Bryan Coon, Tom Wolfe, Jacob Petersen, Thomas Dyrberg, Michael J. Grusby, Matthias G. von Herrath

    Almmustuhtton 1999
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors

    A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors Dahkki Jeffrey S. Weber, Nicholas J. Vogelzang, Marc S. Ernstoff, Oscar B. Goodman, Lee D. Cranmer, John L. Marshall, Sabrina Miles, Dar Rosario, David C. Diamond, Zhiyong Qiu, Mihail Obrocea, Adrian Bot

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

    Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Dahkki James N. Kochenderfer, Robert Somerville, Tangying Lu, James C. Yang, Richard M. Sherry, Steven A. Feldman, Lori McIntyre, Adrian Bot, John M. Rossi, Norris Lam, Steven A. Rosenberg

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial

    Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial Dahkki Antoni Ribas, Jeffrey S. Weber, Bartosz Chmielowski, Begonya Comin-Anduix, David Lu, Michael Douek, Nagesh Ragavendra, Steve Raman, Elizabeth Seja, Darlene Rosario, Sabrina Miles, David C. Diamond, Zhiyong Qiu, Mihail Obrocea, Adrian Bot

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Antigen kinetics determines immune reactivity

    Antigen kinetics determines immune reactivity Dahkki Pål Johansen, Tazio Storni, Lorna Rettig, Zhiyong Qiu, Ani Der-Sarkissian, Kevin M. Smith, Vania Manolova, Karl S. Lang, Gabriela Senti, Beat Müllhaupt, Tilman Gerlach, Roberto F. Speck, Adrian Bot, Thomas M. Kündig

    Almmustuhtton 2008
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy

    Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy Dahkki Pei-Hsuan Chen, Mikel Lipschitz, Jason L. Weirather, Caron A. Jacobson, Philippe Armand, Kyle Wright, F. Stephen Hodi, Zachary Roberts, Stuart A. Sievers, John M. Rossi, Adrian Bot, William Y. Go, Scott J. Rodig

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

    Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL Dahkki John M. Rossi, Patrick Paczkowski, Yueh-wei Shen, Kevin Morse, Brianna Flynn, Alaina Kaiser, Colin Ng, Kyle Gallatin, Tom Cain, Rong Fan, Sean Mackay, James R. Heath, Steven A. Rosenberg, James N. Kochenderfer, Jing Zhou, Adrian Bot

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma Dahkki Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go

    Almmustuhtton 2017
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy

    A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy Dahkki Ranjan Upadhyay, Jonathan Boiarsky, Gvantsa Pantsulaia, Judit Svensson‐Arvelund, Matthew J. Lin, Aleksandra Wroblewska, Sherry Bhalla, Nathalie Scholler, Adrian Bot, John M. Rossi, Norah Sadek, Samir Parekh, Alessandro Laganá, Alessia Baccarini, Miriam Mérad, Brian D. Brown, Joshua Brody

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

    Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma Dahkki Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation

    IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation Dahkki Caitlin M. Tilsed, Barzan A. Sadiq, Tyler E. Papp, Phurin Areesawangkit, Kenji Kimura, Estela Noguera-Ortega, John Scholler, Nicholas Cerda, Haig Aghajanian, Adrian Bot, Barbara L. Mui, Ying K. Tam, Drew Weissman, Carl H. June, Steven Μ. Albelda, Hamideh Parhiz

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses

    Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses Dahkki Gabrielle Romain, Paolo Strati, Ali Rezvan, Mohsen Fathi, Irfan Bandey, Jay R T. Adolacion, Darren Heeke, Ivan Liadi, Mario L. Marques‐Piubelli, Luisa M. Solis, Ankit Mahendra, Francisco Vega, Laurence J.N. Cooper, Harjeet Singh, Mike Mattie, Adrian Bot, Sattva S. Neelapu, Navin Varadarajan

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)

    Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7) Dahkki Simone Filosto, Saran Vardhanabhuti, Miguel Canales, Xavier Poiré, Lazaros J. Lekakis, Sven de Vos, Craig A. Portell, Zixing Wang, Christina To, Marco Schupp, Soumya Poddar, Tan Trinh, Carmen M. Warren, Ethan G. Aguilar, Justin A. Budka, Paul Cheng, Justin Chou, Adrian Bot, Rhine R. Shen, Jason R. Westin

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

    Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma Dahkki Jennifer N. Brudno, Norris Lam, Danielle Vanasse, Yueh-wei Shen, Jeremy J. Rose, John M. Rossi, Allen Xue, Adrian Bot, Nathalie Scholler, Lekha Mikkilineni, Mark Roschewski, Robert M. Dean, Raúl E. Cachau, Philippe Youkharibache, Rashmika Patel, Brenna Hansen, David F. Stroncek, Steven A. Rosenberg, Ronald E. Gress, James N. Kochenderfer

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

    Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma Dahkki Max S. Topp, Tom van Meerten, Roch Houot, Monique C. Minnema, Krimo Bouabdallah, Pieternella J. Lugtenburg, Catherine Thiéblemont, Martin Wermke, Kevin Song, Irit Avivi, John Kuruvilla, Ulrich Dührsen, Yan Zheng, Saran Vardhanabhuti, Jinghui Dong, Adrian Bot, John M. Rossi, Vicki Plaks, Marika Sherman, Jenny J. Kim, A. Kerber, Marie José Kersten

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: